natgillin/translations-raw huggingface dataset:
Interferonerne alfa og beta klassificeres som type I-interferoner, og interferon gamma er et type II-interferon.
Interferons alpha and beta are classified as Type I interferons and interferon gamma is a Type II interferon.
Interferonet i Plegridy fremstilles ved “rekombinant DNA-teknologi”.
The interferon in Plegridy is produced by a method known as ‘recombinant DNA technology’.
Interferonneutraliserende faktorer:
Interferon neutralising factors
Intergrase hæmmer af genoverførelse
Integrase strand transfer inhibitor
Intergrasehæmmer af genoverførelse
CCR5 antagonist
Intergrasehæmmer af genoverførelse
Integrase strand transfer inhibitor
Interim
17.8)
Interim IDMC-analyse, når halvdelen af patienterne når uge 76:
Interim IDMC analysis when half of the patients reach W76: 2Q 2018
Interim OS (52 % modenhed)
Interim OS (52% maturity)
Interimanalyse 1:
Interim analysis
Interimanalyse af OS udført med 40% af de samlede hændelser, der var påkrævet til den endelige analyse.
Interim OS analysis conducted at 40% of total events required for final analysis.
Interime studierapporter – med hver PSUR
Interim Study Reports - with each PSUR
Interimrapporter forventes årligt inden for PSUR’er
Interim reports expected yearly within PSURs
Interimsrapporter: forelægges årligt.
and physicians.
Interkraniel blødning under trombocytopeni
Intracranial haemorrhage while thrombocytopenic
Interkurrente hændelser, særligt dehydrering, akut hjertedekompensation, metabolisk acidose, forværret nyrefunktion, pludselig forværring af nyretilstanden (f.eks. infektionssygdomme), cellenedbrydning (f.eks. akut iskæmi i ekstremiteter, rabdomyolyse, længerevarende trauma).
Intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extensive trauma).
Interkurrente hændelser, særligt dehydrering, akut hjertedekompensation, metabolisk acidose, forværret nyrefunktion, pludselig forværring af nyretilstanden (f.eks. infektionssygdomme), cellenedbrydning (f.eks. akut iskæmi i ekstremiteter, rabdomyolyse, længervarende trauma).
Intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extensive trauma).
Interkurrente infektioner, inflammatoriske eller traumatiske hændelser, okkult blodtab, hæmolyse, aluminiums- forgiftning, underliggende hæmatologiske sygdomme eller knoglemarvsfibrose kan også nedsætte det erytropoietiske respons.
Intercurrent infections, inflammatory or traumatic episodes, occult blood loss, haemolysis, aluminium intoxication, underlying haematological diseases or bone marrow fibrosis may also compromise the erythropoietic response.
Interleukin-2 (IL-2): 3 MIE/m2/dag administreret ved kontinuerlig intravenøs infusion over 96 timer på dag 1-4 og 4,5 MIE/m2/dag på dag 8-11.
Interleukin-2 (IL-2): 3 MIU/m2/day administered by continuous intravenous infusion over 96 hours on Days 1-4 and4.5 MIU/m2/day on Days 8-11.
interleukin-2 (til behandling af kræft)
interleukin-2 (to treat cancer)
interleukin-2 (til behandling af kræft)
interleukin-2 (to treat cancer).
interleukin-2 (til behandling af kræft), adefovirdipivoxil (mod HBV),
interleukin-2 (to treat cancer), adefovir dipivoxil (for HBV),
interleukin-2 også kaldet aldesleukin (til behandling af kræft) non-steroide antiinflammatoriske midler (NSAID’er, til at lindre knogle- eller muskelsmerter)
interleukin-2, also called aldesleukin (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
interleukin-2, som også kaldes aldesleukin (til behandling af kræft) non-steroide antiinflammatoriske midler (NSAID’er, til at lindre knogle- eller muskelsmerter)
interleukin-2, also called aldesleukin (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
Interleukin-6 er et pleiotropisk pro-inflammatorisk cytokin, der dannes af en lang række celletyper inklusive T-celler og B-celler, lymfocytter, monocytter og fibroblaster samt maligne celler.
Interleukin-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T-cells and B-cells, lymphocytes, monocytes and fibroblasts, as well as malignant cells.
INTERMEDIÆR KARTON (uden blå boks) del af flerstykspakning - Cylinderampul
INTERMEDIATE CARTON (without blue box) component of multipack- Cartridge
INTERMEDIÆR KARTON (uden blå boks) del af flerstykspakning - FYLDT INJEKTIONSSPRØJTE
INTERMEDIATE CARTON (without Blue Box) component of a multipack - PRE-FILLED SYRINGE
INTERMEDIÆR KARTON (uden blå boks) del af flerstykspakning - FYLDT PEN
INTERMEDIATE CARTON (without Blue Box) component of a multipack - PRE-FILLED PEN
INTERMEDIÆR KARTON (uden blå boks) del af flerstykspakning - KwikPen
INTERMEDIATE CARTON (without blue box) component of a multipack – KwikPen
INTERMEDIÆR KARTON(uden blå boks) del af en flerstykspakning- KwikPen
INTERMEDIATE CARTON (without blue box) component of a multipack – KwikPen
INTERMEDIÆR ÆSKE (UDEN BLÅ BOKS – DEL AF MULTIPAKNING)
INTERMEDIATE CARTON (WITHOUT BLUE BOX – COMPONENT OF MULTIPACK)
INTERMEDIÆR ÆSKE (UDEN BLÅ BOX) KUN MULTIPAKNING (2X98 TABLETTER)
INTERMEDIATE CARTON (WITHOUT BLUE BOX) MULTIPACKS ONLY (2X98 TABLETS)
INTERMEDIÆR ÆSKE AF MULTIPAKNING (UDEN BLUE BOX)
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
Intermitterende allergisk rhinitis (tilstedeværelse af symptomer i mindre end 4 dage per uge eller i mindre end 4 uger) bør behandles i overensstemmelse med vurderingen af patientens sygdomshistorie, og behandlingen kan afbrydes efter symptomerne er forsvundet og genoptages efter deres tilbagevenden.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Intermitterende allergisk rhinitis (tilstedeværelse af symptomer i mindre end 4 dage per uge eller i mindre end 4 uger) bør behandles ud fra vurdering af patientens sygehistorie, og behandlingen kan afbrydes efter symptomerne er forsvundet og genoptages ved tilbagevenden.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Intermitterende pauser i behandlingen eller nedsættelse af filgrastimdosis bør overvejes hos patienter, der udvikler trombocytopeni, dvs. patienter, der får et vedvarende trombocyttal på < 100 x 109/l..
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm3.
Intern analytisk præcision skal være under +/- 0,3 ‰ 13C for 20 gentagne analyser af samme referencegasprøve og skal forblive inden for 3SD'er af gennemsnittet for UBT-analysen.
Internal analytical precision must be less than + 0.3 ‰ 13C for 20 replicate analyses of the same reference gas sample and remain within 23SD’s of the mean for breath analyses.
Intern analytisk præcision skal være under +/- 0,3 ‰ 13C for 20 gentagne analyser af samme referencegasprøve og skal forblive inden for 3SD'er af gennemsnittet for UBT-analysen.
Internal analytical precision must be less than + 0.3 ‰ 13C for 20 replicate analyses of the same reference gas sample and remain within 3SD’s of the mean for breath analyses.
Internalisering og frigørelse af toksinet i nerveendernes cytosol.
Internalisation and release of the toxin into the cytosol of the nerve terminals
International normaliseret ratio (INR) Op til 12 timer
International normalized ratio (INR) Up to 12 hours
International normaliseret ratio (INR) skal nøje monitoreres efter initiering af dronedaron hos patienter, der får K-vitamin- antagonister.
International Normalised Ratio (INR) should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per their label.
International retrospektive undersøgelse (2006)
International Retrospective Study (2006)
Internationale enheder fastsættes ved at sammenligne aktiviteten af rekombinant interferon alfa-2b med aktiviteten af den internationale referencestandard af human leukocyt interferon fastsat af verdenssundhedsorganisationen WHO.
International Units are determined by comparison of the activity of the recombinant interferon alfa-2b with the activity of the international reference preparation of human leukocyte interferon established by the World Health Organisation.
Internationalt fællesnavn (INN): Telithromycin Sammendrag
International Nonproprietary Name (INN): Telithromycin Abstract
Internationalt normaliseret ratio forhøjet
International normalised ratio increased
Internationalt retrospektivt studie (2006)
International Retrospective
Interstitiel lunge- sygdom, herunder pneumonitis og allergisk alveolitis
Interstitial lung disease including pneumonitis and allergic alveolitis
Interstitiel lungebetændelse (lungebetændelse med talrige små udbredte infektionsområder mellem alveolerne)
Interstitial pneumonitis (scarring of the air sacs of the lung)
Interstitiel lungebetændelse (tør hoste uden slim pga. betændelse i lungernes bindevæv)
Interstitial pneumonitis (scarring of the air sacs of the lung)
Interstitiel lungesyg- dom
Hyperaesthe
interstitiel lungesygdom
interstitial lung disease,
Interstitiel lungesygdom (akut respiratorisk distress-syndrom, alveolitis, interstitiel lungesygdom, pneumonitis)
Interstitial lung disease (Acute respiratory distress syndrome, Alveolitis, Interstitial lung disease, Pneumonitis).
Interstitiel lungesygdom (betændelse i lungerne, der forårsager hoste og vejrtrækningsbesvær.
Frequency unknown: interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing.
Interstitiel lungesygdom (inflammation i vævet omkring lungernes alveoler)
Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)
interstitiel lungesygdom (nogle tilfælde kan være fatale)
interstitial lung disease (some cases have been fatal)
Interstitiel lungesygdom (sygdom i alveolevævet).
Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)
Interstitiel lungesygdom (sygdom i alveolevævet).
Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs).
Interstitiel lungesygdom*
interstitial lung disease
Interstitiel lungesygdom**
Interstitial lung disease
Interstitiel lungesygdom*,#,a
Tumour lysis syndrome Hyperuricaemia
interstitiel lungesygdom,
interstitial lung disease,
interstitiel lungesygdom, herunder pulmonal fibrose
interstitial lung disease, including pulmonary fibrosis
interstitiel lungesygdom, pneumonitis
interstitial lung disease, pneumonitis
Interstitiel lungesygdom/pneumo nitis†
Interstitial lung disease/pneumonitis
Interstitiel lungesygdom/pneumoni.
Interstitial lung disease/pneumonitis.
Interstitiel lungesygdom/pneumonitis†
Interstitial lung disease/pneumonitis
interstitiel lungesygdom3
interstitial lung disease3
interstitiel lungesygdom7
irritation
interstitiel lungesygdom7
lung disorder,
Interstitiel lungesygdoma
Interstitial lung diseasea
Interstitiel lungesygdomc
Interstitial lung diseasec
Interstitiel lungesygdomi (3%)
Interstitial lung diseasei (3%)
Interstitiel nefritis, nyreinsufficiens
Musculoskeletal and connective tissue disorders:
Interstitiel pneumoni*
Interstitial pneumonitis
Interstitiel pneumonitis
Interstitial pneumonitis
Interstitiel pneumonitis inklusiv dødelig udgang, lungeemboli
Interstitial pneumonitis including fatal outcome, pulmonary embolism
Interstitiel pneumonitis/pneumonitis, lungefibrose, respirationsinsufficiens†
interstitial pneumonitis/pneumonitis, pulmonary fibrosis, respiratory failure
Interstitielle lungesygdomme
Intersticial pneumopathies
Interval af administreret vedligeholdelses dosis meloxicam (mg/kg)*
Maintenance dosage range meloxicam delivered (mg/kg)
Interval for legemsoverfladeareal (BSA) (m2)
Body Surface Area (BSA) range (m2)
Interval på 50-200 %, hvor der ikke er farmakokinetisk interaktion.
Lack of pharmacokinetics interaction bounds 50-200%.
Interval på 70-143 %, hvor der ikke er farmakokinetisk interaktion.
Lack of pharmacokinetics interaction bounds 70-143%.
Interval på 70-143 %, hvor der ikke opstår farmakokinetisk interaktion.
Lack of pharmacokinetics interaction bounds 70-143%.
Intervaller mellem primære doser
Intervals between Primary Doses
Intervallet mellem den konjugerede pneumokokvaccine (Prevenar) og 23-valent polysaccharid pneumokokvaccine bør ikke være under 8 uger.
The interval between the pneumococcal conjugate vaccine (Prevenar) and the 23- valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Intervallet mellem den konjugerede pneumokokvaccine (Prevenar) og 23-valent polysaccharid pneumokokvaccine må ikke være under 8 uger.
The interval between the pneumococcal conjugate vaccine (Prevenar) and the 23- valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Intervallet mellem den konjugerede pneumokokvaccine (Synflorix) og den 23-valente pneumokokpolysaccharidvaccin bør ikke være under 8 uger.
The interval between the pneumococcal conjugate vaccine (Synflorix) and the 23-valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Intervallet mellem den sidste vedligeholdelsesdosis og den første dosis ved gentagen induktion varierede mellem 35 og 231 dage.
The interval between the last maintenance dose and the first re- induction dose ranged from 35-231 days.
Intervallet mellem injektionerne skal være mindst 1 måned.
The interval between each injection should be at least 1 month.
Intervallet mellem injektionerne skal være mindst 2 måneder.
The interval between each injection should be at least 2 months
Intervallet mellem injektionerne skal være mindst 2 måneder.
The interval between each injection should be at least 2 months.
Intervallet mellem injektionerne skal være mindst en måned.
The interval between each injection should be at least 1 month.
Intervallet mellem injektionerne skal være mindst to måneder.
The interval between the injections should be at least 2 months.
Intervallet mellem to injektioner af Lucentis skal altid være mindst 4 uger.
The interval between two injections of Lucentis into the same eye must be at least four weeks.
Intervallet mellem to injektioner i samme øje skal være mindst fire uger.
The interval between two doses injected into the same eye should be at least four weeks.
Interventionsfri overlevelse i denne pivotale population (defineret som overlevelse uden behov for langvarig ( 3 måneder) genoptagelse af PEG-ADA eller stamcelletransplantation) var 92 % (11/12 forsøgspersoner) (82 % (14/17 forsøgspersoner) for den integrerede population).
Intervention- free survival in this pivotal population (defined as survival without the requirement for long-term (3 month) re-introduction of PEG-ADA, or stem cell transplant) was 92% (11/12 subjects) (82% (14/17 subjects) for integrated population).
Intervertebral diskusprotrusion (NB), kæbesmerter (NB), lyskesmerter (N)
Intervertebral disc protrusion (NB), Jaw pain (NB), Groin pain (N)
Intervet de Bilt Ambachtstraat 2, De Bilt Holland
Intervet de Bilt Ambachtstraat 2, De Bilt The Netherlands
Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer
Intervet International B. V. Wim de Körverstraat 35
Intervet International B.V. Wim de Körverstraat 35 NL – 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer
Intervet International B.V. Wim de Körverstraat 35 NL-5830 AA Boxmeer Holland
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer The Netherlands
Intervet International B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer Holland
Intervet International B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
Intervet International B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer Holland
Intervet International BV Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
Intervet International B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer Holland
Wim de Körverstraat 35 NL - 5831 AN Boxmeer The Netherlands
Intervet International B.V. Wim sw Körverstraat 35 NL-5830 AA Boxmeer Holland
Intervet International B.V. Wim de Körverstraat 35 NL - 5831 AN Boxmeer The Netherlands
Intervet International B.V., NL-5831 AN Boxmeer
Intervet International B.V., NL – 5831 AN Boxmeer
Intervet International BV Wim de Körverstraat 35 NL-5831 AN Boxmeer Holland
Intervet International BV Wim de Korverstraat 35 NL-5831 AN Boxmeer The Netherlands
Intervet International BV Wim de Körverstraat 35 NL-5831 AN Boxmeer Holland
Wim de Körverstraat 35 5831 AN Boxmeer Netherlands
Intervet UK Ltd.
Intervet UK Ltd
Intestinal
Gastrointestina
Intestinal blødning (blødning i tarmsystemet)
Intestinal haemorrage (bleeding in the gut)
Intestinal obstruktion*
Intestinal obstruction
Intestinal obstruktion,
Intestinal obstruction, Ascites, Enteritis,
Intestinal obstruktion, ileus/subileus, tarmperforation
Intestinal obstruction, ileus/subileus, intestinal perforation
intestinal perforation)*;
intestinal
intestinal stenose, colitis, enteritis, oesophagitis
intestinal stenosis, colitis, enteritis, oesophagitis
intestinale infektioner (inklusive viral gastroenteritis),
intestinal infections (including gastroenteritis viral),
Intet anført
No entry
Intet eRVR
No eRVR
Intet fald (FVC-ændring >0 %)
No decline (FVC change >0%)
Intet lys
No light
Intet naturgummilatex er hidtil blevet påvist i den aftagelige kanylehætte.
No natural rubber latex has to date been detected in the removable needle cap.
Intet punktestimat foreligger for resten af studierne.
point estimate was available for the remaining study.
Intet respons
No response
Intet respons ved Intet Negativ behandling vedvarend prædiktiv s uge e respons værdi
No response at No Negative treatment sustained predictive week response value
Intet respons ved Intet Negativ behandlingsu vedvarend prædikti ge e respons v værdi
No response at No Negative treatment sustained predictive week response value
Intet respons ved uge 12
No response by week 12
Intet salg af enkeltpakninger.
No individual sale.
Intet svarc
N/Ac
Intet tegn på leukæmi
No evidence of leukaemia
Intet tegn på leukæmi (NEL)
No evidence of leukaemia
Intet tegn på leukæmi (NEL)
No evidence of leukaemia (NEL)
Intet tegn på leukæmi (NEL) Remission til kronisk fase (RTC)
No evidence of leukaemia (NEL)
Intet tegn på neutropeni ved baseline
No neutropenia at baseline
intet tidligere virologisk svigt
absence of prior virologic failure
Intet tyder på, at særlige sikkerhedsregler skulle være nødvendige ved behandling af ældre, men erfaringerne med Soliris til denne patientpopulation er stadig begrænsede.
There is no evidence to suggest that any special precautions are needed when older people are treated – although experience with Soliris in this patient population is still limited.
Intet uændret fenofibrat kan spores i plasma, hvor hovedmetabolitten er fenofibrinsyre.
No unchanged fenofibrate can be detected in the plasma where the principal metabolite is fenofibric acid.
Intet uændret mitotan er blevet fundet i galde eller i urin, hvor o,p’-DDA prædominerer, sammen med adskillige af dens hydroxylerede metabolitter.
No unchanged mitotane has been found in bile or in urine, where o,p’-DDA predominates, together with several of its hydroxylated metabolites.
Intet ved- varende respons
No sustained response
Intolerance over for kontaktlinser*
Contact lens intolerance
Intolerans
Intolerance
Intolerans over for alkohol
Inability to tolerate alcohol consumption
Intra- individ-variabiliteten (CVw%) er lavere end inter-individ-variabiliteten.
Within-subject variability (CVw%) is lower than between-subject variability.
Intra- og interpatientvariabiliteten er lav.
Intra-patient and inter-patient variability is low.
Intra-abdominal blødning
Haemorrhoidal haemorrhage, mouth haemorrhage
Intra-abdominal blødning Lokaliseret intra-abdominal væskeansamling
Intra-abdominal haemorrhage Localised intra-abdominal fluid collection Peripancreatic fluid collection
Intra-abdominale infektion
Intraabdominal Infections (IAI)
Intraarteriel anvendelse, Intravenøs anvendelse, Subkutan anvendelse
Intraarterial use, Intravenous use, Subcutaneous use
Intracellulær ara- GTP Cmax og AUC(0-t)-værdier på samme dosisniveau var 2 – 3 gange større i gennemsnit hos voksne kvindelige patienter end hos voksne mandlige patienter.
Intracellular ara-GTP Cmax and AUC(0–t) values at the same dose level were 2– to 3– fold greater on average in adult female than in adult male patients.
Intracellulær Cmax for ara-GTP blev set i løbet af 3 – 25 timer på dag 1.
Intracellular Cmax for ara-GTP appeared within 3 to 25 hours on day 1.
Intracellulær farmakokinetik: I en klinisk studier var emtricitabin-triphosphats intracellulære halveringstid i mononukleære celler i perifert blod 39 timer.
Intracellular pharmacokinetics: In a clinical study, the intracellular half-life of emtricitabine-triphosphate in peripheral blood mononuclear cells was 39 hours.
Intracellulær hydrolytisk prodrug- kløvning katalyseret af enzymer, herunder carboxylesterase 1 og sekventiel fosforyleringstrinkatalyseret af nukleotidkinaser fører til dannelsen af det farmakologisk aktive uridin- nukleosidanalog-triphosphat.
Intracellular hydrolytic prodrug cleavage catalysed by enzymes including carboxylesterase 1 and sequential phosphorylation steps catalysed by nucleotide kinases result in formation of the pharmacologically active uridine nucleoside analogue triphosphate.
intracellulær kompleks.
considered.
Intracellulær koncentration af cladribine overstiger koncentration i plasma med 128 til 375 gange.
Intracellular concentration of cladribine exceeds its plasma concentration by 128 to 375 times.
Intradermal anvendelse
Intradermal use
Intradermal anvendelse, subkutan anvendelse, intratumoral anvendelse, peritumoral anvendelse
Intradermal use, Intratumoral use, Peritumoral use, Subcutaneous use
Intrakranial blødning
Intracranial haemorrhage
Intrakranial hæmoragi forekom 0,93 % imod 0,94 % for henholdsvis tenecteplase og alteplase.
0.94% for tenecteplase and alteplase, respectively.
intrakranial neoplasme, arteriovenøs misdannelse eller aneurisme
intracranial neoplasm, arteriovenous malformation or aneurysm
Intrakraniel
haemorrhag
Intrakraniel
Intracrani
Intrakraniel
Intracranial
Intrakraniel
oneal
Intrakraniel
Retroperit
Intrakraniel
Retroperitoneal
Intrakraniel
ural
Intrakraniel aneurisme Ekstrapyramidale symptomer Kognitiv forstyrrelse Hjerneblødning
Intracranial aneurysm Extrapyramidal disorder
Intrakraniel blødning (nogle med dødelig udgang), hovedpine, paræstesi, svimmelhed
Eye bleeding (conjunctival, ocular, retinal)
Intrakraniel blødning (nogle med fatal udgang), hovedpine, paræstesi, svimmelhed
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
Intrakraniel blødning (nogle med letal udgang), hovedpine, paræstesier, svimmelhed
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
Intrakraniel blødning blev rapporteret hos 1% af patienter, der har været eksponeret for Jakavi og hos 0,9% eksponeret for referencebehandlinger.
Intracranial bleeding was reported in 1% of patients exposed to Jakavi and 0.9% exposed to reference treatments.
Intrakraniel blødning efter protokol
Intracranial haemorrhage after protocol
Intrakraniel blødning under trombocytopeni*
Intracranial haemorrhage while thrombocyto- penic
Intrakraniel blødning*
Intracranial haemorrhage
Intrakraniel blødning: Spontane intrakranielle blødninger blev rapporteret i samme størrelsesorden for ticagrelor 60 mg og for ASA-behandling alene (n=13, 0,2 % i begge behandlingsgrupper).
Intracranial bleeding: Spontaneous ICHs were reported in similar rates for ticagrelor 60 mg and ASA therapy alone (n=13, 0.2% in both treatment groups).